Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs

Retrieved on: 2021-07-13 15:45:00

Tags for this article:

Life Sciences

Health care

Companies

Monoclonal antibodies

Spinal muscular atrophy

Biogen

Dimethyl fumarate

Sanofi

Bruton's tyrosine kinase

Aducanumab

Interferon beta-1a

Daclizumab

Click the tags to see associated articles and topics

Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs. View article details on HISWAI: https://www.biopharmadive.com/news/biogen-innocare-multiple-sclerosis-btk-inhibitor/603215/

Excerpt

Biogen gets royalties on sales of Roche's Ocrevus, which is fast becoming the top-selling MS drug globally. But the biotech company has been working ...

Article found on: www.biopharmadive.com

View Original Article